Bio Business

» pharma, tuberculosis and cancer

Most Recent

image: The Growth of Iowa Biotech

The Growth of Iowa Biotech

By | August 1, 2016

The state’s industry draws inspiration from medicine as well as agriculture.

1 Comment

image: Banking on Blood Tests

Banking on Blood Tests

By | April 1, 2016

How close are liquid biopsies to replacing current diagnostics?

1 Comment

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

1 Comment

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

image: Outwitting the Perfect Pathogen

Outwitting the Perfect Pathogen

By | January 1, 2014

Tuberculosis is exquisitely adapted to the human body. Researchers need a new game plan for beating it.

0 Comments

image: The Little Cell That Could

The Little Cell That Could

By | July 1, 2012

Critics point out that cell therapy has yet to top existing treatments. Biotech companies are setting out to change that—and prove that the technology can revolutionize medicine.

1 Comment

image: Make Mine Rare

Make Mine Rare

By | August 1, 2011

With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.

6 Comments

image: Take Two of These

Take Two of These

By | June 22, 2011

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.

3 Comments

image: The Profits of Nonprofit

The Profits of Nonprofit

By | January 1, 2011

The surprising results when drug development and altruism collide

9 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech